Two companies supported by HiTT get outstanding reward.

Two companies supported by HiTT get outstanding reward.

HiTT celebrates that Barcelona Activa recognizes Qbeast with an award for the best project of high technological impact and Hospital Vall d’Hebron obtains more than 1M€ benefit from the exploitation of a patent license.  Qbeast is a ‘Big Data’ analysis platform that allows the indexation and visualization of data in a responsive, clear and intuitive way.   On  February, Barcelona Activa has awarded the Qbeast startup for the best business project with a high technological impact, with an economic contribution of 5.000€, in the framework of the fifth edition of the Preacceleració Program. Qbeast has also obtained an office space in the MediaTIC Incubator. HiTT has pleased worked all along with Qbeast to define its business model and its development path.  Also in February Hospital Vall d’Hebron has published that Hospital Vall d’Hebron has obtained more than € 1M benefit from the licence of a new treatment for a rare disease, representing the highest economic benefit generated by a state research institute by a patent licence. Doctors Ramon Martí (VHIR) and Michio Hirano (Columbia University) discovered the treatment in 2013. Afterwards, they licenced the patent to Modis Therapeutics, an American company, to develop the therapy. HiTT participated in the evidence review to complete the evidence package of the value dossier of the drug.   These two successful stories reinforce the idea of Barcelona as a strong life sciences and health HUB articulated around powerful core formed by public hospitals, pharmaceutical companies and research centres with which HiTT has strong and long-standing relationships.  HiTT is an international market access consultancy with a payer perspective, with offices in Barcelona born in 2013. HiTT focuses its main activity on advising and accompanying institutions, research centres and private companies in the health sector, who wish to develop and implement innovative projects to add value to the health...
Big Data analytical tools project

Big Data analytical tools project

Health Innovation Technology Transfer (HITT) is working on the development of an European project in Big Data tools. This project tries to understand the needs of the professionals that use Big Data tools in its analytical procedures. In order to know which are the needs and the characteristics of the companies that use Big Data analytical tools, HiTT is developing this study through interviews to professionals of different sectors and also, through on-line questionnaires that people that is interested in this topic can answer. We would like to gather as much information as possible to ensure that our analysis reflects the real concerns of the market. HiTT invites the professionals that use big data tools in its analytical procedure, to open this link and answer the questionnaire. Your responses will be kept anonymous. Many thanks in...
ISPOR 20th annual European congress

ISPOR 20th annual European congress

From 4th to 8th November 2017 it will be held in Glasgow, Scotland, the ISPOR 20th annual European congress. ISPOR is recognized globally as the leading scientific and educational organization for HEOR (health economics and outcomes research) and its use in health care decisions. ISPOR Glasgow provides a forum for discussion and dissemination of HEOR information. The congress is a great opportunity collaborate and network with colleagues in the field, and hear about innovative research methods and new health policy developments. Reflecting on revolutionary transformations affecting today’s health care, ISPOR Glasgow will address medical technology development, health technology assessment, and policy and clinical decision making while exploring the theme, The Evolution of Value in Health Care. Dr. Sola Morales will discuss about the topic that in 1999, the EU enacted legislation to foster the introduction of new Orphan Medicinal Products (OMP) into the market. To date only partial evaluations of the success of this legislation have been made, so this analysis investigates the outcomes of the OMP legislation from a broader perspective. It is possible to find the program in this...
Assessing the Value of New Antibiotics

Assessing the Value of New Antibiotics

Dr. Solà-Morales Serra has participated in the formulation of a new study called, Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions. The study wants to highlight the key challenges with the current approaches to assessing the clinical, economic and health system value of antibiotics. The study faces the actual approaches, and proposes additional elements of value that address these challenges from all relevant perspectives. To conclude the analysis, the paper suggests the next steps needed to refine and implement the additional concepts proposed. This paper was developed by a project team, which included partners from the pharmaceutical industry. The brienfing is available in this web...
Drug’s public procurement study

Drug’s public procurement study

Dr. Solà-Morales Serra has participated in the formulation of a new study that explains the innovative approach of drug’s public procurement. This study analyses the sharing agreements, and the payments in exchange of results. The study provides also an indicative guide that helps to identify which approach or approaches are the most recommended to each situation. The study describes too, the most used solutions in the European industry. The study is available in the following web address: http://www.ieseinsight.com/fichaMaterial.aspx?pk=139748&idi=1&origen=3&ar=7&buscador=2&keywords=&autores=&titulo=&referencia=&fPublicacionMesInf=&fPublicacionAnyoInf=&fPublicacionMesSup=&fPublicacionAnyoSup=&idiomaB=&idiomaBT=&area=&tipo=&tipoT=&deps=&publicadoPor=&catedra=CRHIM+-+Center+for+Research+in+Healthcare+Innovation+Management  ...